科伦博泰生物：自研药物SKB103获批临床，用于治疗晚期实体瘤

财中社03-24

3月24日，科伦博泰生物（06990）发布公告，公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原的双特异性抗体偶联药物（bsADC） SKB103的新药临床试验申请已获国家药品监督管理局药品审评中心（CDE）批准，用于治疗晚期实体瘤。　　公告指出，这是公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。作为ADC领域的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2621050900?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-24 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621050900","market":"sh","top_or_hot":-1,"title":"科伦博泰生物：自研药物SKB103获批临床，用于治疗晚期实体瘤","media":"财中社","content":"<div>\n<p>3月24日，科伦博泰生物（06990）发布公告，公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原的双特异性抗体偶联药物 （bsADC） SKB103的新药临床试验申请已获国家药品监督管理局药品审评中心 （CDE） 批准，用于治疗晚期实体瘤。　　公告指出，这是公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。作为ADC领域的...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603243682629398.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科伦博泰生物：自研药物SKB103获批临床，用于治疗晚期实体瘤</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科伦博泰生物：自研药物SKB103获批临床，用于治疗晚期实体瘤\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-24 17:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202603243682629398.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月24日，科伦博泰生物（06990）发布公告，公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原的双特异性抗体偶联药物 （bsADC） SKB103的新药临床试验申请已获国家药品监督管理局药品审评中心 （CDE） 批准，用于治疗晚期实体瘤。　　公告指出，这是公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。作为ADC领域的...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603243682629398.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDE","symbol_name":"科尔黛伦矿业","start_time":0,"source_url":"http://finance.eastmoney.com/a/202603243682629398.html","article_id":"2621050900","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621050900","pubTimestamp":1774343040,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"3月24日，科伦博泰生物（06990）发布公告，公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原的双特异性抗体偶联药物（bsADC）SKB103的新药临床试验申请已获国家药品监督管理局药品审评中心（CDE）批准，用于治疗晚期实体瘤。公告指出，这是公司首个进入临床阶段的TAA-PD-L1bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CDE":"科尔黛伦矿业","RDC":"罗文","BK4017":"黄金","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","LU1223082196.USD":"施罗德环球黄金A Acc"},"translate_title":"Kelunbotai Biologics: Self-developed drug SKB103 approved for clinical use for the treatment of advanced solid tumors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDE":1,"RDC":1},"content_text":"3月24日，科伦博泰生物（06990）发布公告，公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原的双特异性抗体偶联药物 （bsADC） SKB103的新药临床试验申请已获国家药品监督管理局药品审评中心 （CDE） 批准，用于治疗晚期实体瘤。　　公告指出，这是公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。作为ADC领域的行业领军者之一，公司已建立起坚实的领先优势。　　与此同时，公司着眼于肿瘤治疗的迭代升级，持续拓展创新布局，构建了涵盖放射性核素偶联药物 (RDC)、bsADC 等前沿疗法的多元化管线矩阵，全力推动肿瘤现有治疗模式的突破与革新。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621050900","isCrawlerRequest":true}